Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. Juli 2018 07:00 ET | Quelle: Valeritas, Inc.

Valeritas to Report Second Quarter 2018 Results August 7, 2018

BRIDGEWATER, N.J., July 24, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device---a simple, all-in-one,...
25. Juni 2018 07:00 ET | Quelle: Valeritas, Inc.

Valeritas ENABLE Study Demonstrates Significant Clinical Benefits of V-Go in Patients with Type 2 Diabetes Who Switched from Insulin Pens and Syringes

BRIDGEWATER, N.J., June 25, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device—a simple, all-in-one,...
23. Mai 2018 07:00 ET | Quelle: Valeritas, Inc.

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Positive Clinical and Economic Benefits in Patients with Type 2 Diabetes

BRIDGEWATER, N.J., May 23, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with type 2 diabetes V-Go® Wearable Insulin Delivery...
21. Mai 2018 07:00 ET | Quelle: Valeritas, Inc.

Valeritas Announces V-Go® Distribution Agreement in Austria and Germany

BRIDGEWATER, N.J., May 21, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with diabetes V-Go® Wearable Insulin Delivery device, a...
18. Mai 2018 07:00 ET | Quelle: Valeritas, Inc.

Valeritas Announces Positive Clinical Results Across Two New Studies Evaluating V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes

BRIDGEWATER, N.J., May 18, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers V-Go® Wearable Insulin Delivery device, a simple, all-in-one...
14. Mai 2018 07:00 ET | Quelle: Valeritas, Inc.

Valeritas’ V-Go® Wearable Insulin Delivery Device Results in Clinical Benefits Sustained Over Time in Patients with Diabetes

BRIDGEWATER, N.J., May 14, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with diabetes V-Go® Wearable Insulin Delivery device, a...
09. Mai 2018 16:01 ET | Quelle: Valeritas, Inc.

Valeritas Reports Record First Quarter Revenue with 32% Year-over-Year Growth and Gross Margins Expand to Record 47.6%

BRIDGEWATER, N.J., May 09, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with diabetes V-Go® Wearable Insulin Delivery device, a...
01. Mai 2018 07:00 ET | Quelle: Valeritas, Inc.

Valeritas to Report First Quarter 2018 Results on May 9, 2018

BRIDGEWATER, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with diabetes V-Go® Wearable Insulin Delivery device, a...
30. April 2018 07:00 ET | Quelle: Valeritas, Inc.

Valeritas Presented New Data Demonstrating use of V-Go® Wearable Insulin Delivery Device Results in More Patients with Type 2 Diabetes Achieving Blood Glucose Targets

BRIDGEWATER, N.J., April 30, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with diabetes V-Go® Wearable Insulin Delivery device,...
24. April 2018 07:00 ET | Quelle: Valeritas, Inc.

Valeritas Announces Pricing of $24 Million Public Offering of Common Stock

BRIDGEWATER, N.J., April 24, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with type 2 diabetes V-Go® Wearable Insulin Delivery...

Vorherige Seite

Nächste Seite